New research on the ties between bacteria and inflammatory disease.
Educational Leader Honored with Top Rheumatology Award
Paul Emery, MA, MD, receives prestigious Nachman Prize.
Drug Updates: EULAR 2012
Tracking the results of drug safety and efficacy
ACR/ARHP Annual Meeting Offers Basic Science Track
The ACR/ARHP Annual Meeting is the premier event for specialists in the field of rheumatology, and at this year’s meeting, basic researchers will be afforded multiple opportunities to increase their knowledge.
Minerals, Mud, Martinis, and Methylprednisone
How the practice of rheumatology differs in America and Europe.
Bringing Fellows-in-Training to the Annual Meeting
The ACR supports fellows-in-training who wish to attend the ACR/ARHP Annual Meeting through the ACR Fellows Education Fund.
ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases
Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.
Pinpoint Cognitive Dysfunction in Patients with Lupus
More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. “Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.
First ARHP ‘Best of the Meeting’ Highlights Sleep Research, Osteoporosis Screening, More
“The line between ACR and ARHP sessions has totally blurred,” said Donah Zack Crawford, MA, during the presentation, “Highlights from the 2011 ARHP Sessions,” here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November 2011.
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 91
- Next Page »